Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

Uses:

-For the treatment of advanced renal cell carcinoma (RCC)

-For the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib.

Usual Adult Dose for Gastrointestinal Stromal Tumor:

50 mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

Comment: May be taken with or without food.

Uses:

-For the treatment of advanced renal cell carcinoma (RCC)

-For the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib.

Usual Adult Dose for Pancreatic Cancer:

37.5 mg orally once daily

Comments:

-To be taken continuously without a scheduled off-treatment period; may be taken with or without food.

Use: For the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.